Effect of Dihydropyridine Calcium Channel Blockers (CCB) on the Progression of Diabetic Nephropathy in Aranyaprathet Hospital, Sakeaw Province, Thailand

Teerapon Pattanapisansak

doi:doi:10.11648/j.ajim.20241203.12

Research Article |

| Peer-Reviewed

Effect of Dihydropyridine Calcium Channel Blockers (CCB) on the Progression of Diabetic Nephropathy in Aranyaprathet Hospital, Sakeaw Province, Thailand

Teerapon Pattanapisansak^*

Published in American Journal of Internal Medicine (Volume 12, Issue 3)

Received: 20 July 2024 Accepted: 24 August 2024 Published: 11 September 2024

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Importance From Thailand, has standardized therapeutic drugs of Calcium channel blockers (CCB) in reduce the progression of chronic renal failure in diabetic and hypertension that is advantages for use in patients. However, use of Amlodipine that is more accessible and also a drug used by all community hospitals to treat patients, inexpensive and highly effective. Objective To study effective of Dihydropyridine Calcium channel blockers (CCB) on kidney function (eGFR), urinary protein creatinine and sugar blood level. Design, Setting, and Participants This study is retrospective cohort study by study in patients with diabetic nephropathy. By study in patients with diabetes nephropathy with stage 3 or higher and receiving Dihydropyridine Calcium channel blockers (CCB). Exposures Dihydropyridine Calcium channel blockers (CCB) in reducing the complications of diabetic nephropathy which is consistent with Strategy No.2 Providing quality and excellent health services. And literature reviews in Thailand have not found empirical evidence that mean Calcium Channel can reduce the complications of diabetic nephropathy. Main Outcomes and Measures The effectiveness of Dihydropyridine Calcium channel blockers (CCB) increases the complications of diabetic nephropathy. Results In volunteer, female patient proportion was 69.0%. Average age was 69.3 (± 9.69), minimum age is 40 years, maximum age is 97 years. Most patients were between 60-79 years, follow by 40-59 years follow by16.8% and more than 80 years 16.1%. In congenital disease, kidney disease, kidney failure, diabetes and hypertension are 100%, follow by 24% obesity and 0.2% cancer. The effect of Dihydropyridine Calcium channel blockers (CCB) on kidney function (eGFR), urine microalbumin and creatinine when compare with use drug CCB 2 groups including Amlodipine and Amlodipine+enalapril/losartan/valsartan. Found that volunteer that received CCB drug compare with month 3 and 12, the level of eGFR decreases (t=1.085) and Urine Microalbumin increases (t=1.496) by statistically significance (P = 0.002) and Dihydropyridine Calcium channel blockers (CCB) on Fasting blood sugar compares with month 3 and 12, Fasting blood sugar (t = 0.566) and HbA1C (t=0.677) was typically decreased significantly (P < 0.005). Conclusions and Relevance Calcium channel blockers (CCBs) was decline kidney function (decrease eGFR) and CCB leads to the decrease of eGFR and provides monitoring of CCB use, as this may lead to the decrease of kidney function.

Published in	American Journal of Internal Medicine (Volume 12, Issue 3)
DOI	10.11648/j.ajim.20241203.12
Page(s)	33-39
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Effect, Dihydropyridine Calcium Channel Blockers (CCB), Diabetic Nephropathy

References

[1]	Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5): 1047-1053. https://doi.org/10.2337/diacare.27.5.1047
[2]	World Health Organization: Media centre. Fact sheets. Diabetes. http://www.who.int/mediacentre/factsheets/fs312/en/ Accessed sep 30, 2019.
[3]	Ingsathit A, Thakkinstian A, Chaiprasert A, et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant. 2010; 25(5): 1567-1575. https://doi.org/10.1093/ndt/gfp669
[4]	National Health Security office (NHSO), Thailand. National Health Security Fund Management Manual Year 2560; 4: 7–13.
[5]	Centers for Disease Control. Morbidity and Mortality Weekly Report (MMWR). Morb Mortal Wkly Rep, 2013; 62(11), 209-212.
[6]	Ryu S, Song J, Choi BY, et al. Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. Ann Epidemiol. 2007; 17(4): 245-252. https://doi.org/10.1016/j.annepidem.2006.10.001
[7]	Sakeaw Province Public Health Office, Thailand. annual report. 2020.
[8]	A rise in cytosolic Ca2+ is the key event in contraction Explanation: But note that some vasoactive substances may also increase the sensitivity of the contractile machinery to Ca2+.
[9]	Contraction may be caused by agents depolarizing the cell and thus opening voltagedependent Ca2+ channels. Explanation: Ca2+ entry through Ca2+ channels is a target for Ca2+ channel blockers such as nifedipine. (Fig4.10 on p67).
[10]	Bakris GL. Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens. 1996; 5(3): 219-223. https://doi.org/10.1097/00041552-199605000-00006
[11]	Parving HH. The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. J Hypertens. 1990; 8: S187-S191.
[12]	Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995; 123(10): 754-762. https://doi.org/10.7326/0003-4819-123-10-199511150-00003
[13]	Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA. "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int. 1995; 48(3): 851-859. https://doi.org/10.1038/ki.1995.361
[14]	Zing W, Ferguson RK, Vlasses PH. Calcium antagonists in elderly and black hypertensive patients. Therapeutic controversies. Arch Intern Med. 1991; 151(11): 2154-2162.
[15]	Walker WG, Hermann JA, Anderson JE. Randomized doubly blinded trial of enalaprilvs hydrochlorothiazide on glomerular filtration rate in diabetic nephropathy. Hypertension. 1993; 22: 410.
[16]	Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990; 150(8): 1707-1713.
[17]	Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int. 1989; 35(2): 670-674. https://doi.org/10.1038/ki.1989.37
[18]	Lash JP, Bakris GL. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol Dial Transplant. 1995; 10 Suppl 9: 56-62.
[19]	American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2017; 40(Suppl 1): S11-S24. https://doi.org/10.2337/dc17-S005
[20]	Theerapon Pattanapisansak. Progression of Kidney Disease n Type 2 Diabetic Patients: a Case Study of Aranyaprathet Hospital. Journal of Health Science 2019; 28: 639-49.
[21]	Pornpen Srisawat. Glycated Hemoglobin Stardardization. Journal of the Medical Technologist Association of Thailand, 2007; 35(1), 1763-66.
[22]	Salako BL, Finomo FO, Kadiri S, Arije A, Olatosin AO. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy. Afr J Med Med Sci. 2002; 31(1): 53-57.
[23]	Fogari R, Mugellini A, Zoppi A, et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol. 2005; 61(7): 483-490. https://doi.org/10.1007/s00228-005-0961-2
[24]	De Cesaris R, Ranieri G, Andriani A, et al. Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes. Clin Pharmacol Ther. 1996; 60(4): 472-478. https://doi.org/10.1016/S0009-9236(96)90204-0
[25]	Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res. 2007; 100(3): 342-353. https://doi.org/10.1161/01.RES.0000256155.31133.49
[26]	Hayashi K, Homma K, Wakino S, et al. T-type Ca channel blockade as a determinant of kidney protection. Keio J Med. 2010; 59(3): 84-95. https://doi.org/10.2302/kjm.59.84
[27]	Dietz JR, Davis JO, Freeman RH, Villarreal D, Echtenkamp SF. Effects of intrarenal infusion of calcium entry blockers in anesthetized dogs. Hypertension. 1983; 5(4): 482-488. https://doi.org/10.1161/01.hyp.5.4.482
[28]	Abe Y, Komori T, Miura K, et al. Effects of the calcium antagonist nicardipine on renal function and renin release in dogs. J Cardiovasc Pharmacol. 1983; 5(2): 254-259. https://doi.org/10.1097/00005344-198303000-00015
[29]	Roy MW, Guthrie GP Jr, Holladay FP, Kotchen TA. Effects of verapamil on renin and aldosterone in the dog and rat. Am J Physiol. 1983; 245(4): E410-E416. https://doi.org/10.1152/ajpendo.1983.245.4.E410
[30]	Steinhausen M, Baehr M. Vasomotion and vasoconstriction induced by Ca agonist in the split hydronephrotic kidney. Prog Appl Microcirc. 1989; 14: 25–29.
[31]	Hansen PB, Jensen BL, Andreasen D, Skøtt O. Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res. 2001; 89(7): 630-638. https://doi.org/10.1161/hh1901.097126

Cite This Article

Plain Text BibTeX RIS

APA Style

Pattanapisansak, T. (2024). Effect of Dihydropyridine Calcium Channel Blockers (CCB) on the Progression of Diabetic Nephropathy in Aranyaprathet Hospital, Sakeaw Province, Thailand. American Journal of Internal Medicine, 12(3), 33-39. https://doi.org/10.11648/j.ajim.20241203.12

Copy | Download

ACS Style

Pattanapisansak, T. Effect of Dihydropyridine Calcium Channel Blockers (CCB) on the Progression of Diabetic Nephropathy in Aranyaprathet Hospital, Sakeaw Province, Thailand. Am. J. Intern. Med. 2024, 12(3), 33-39. doi: 10.11648/j.ajim.20241203.12

Copy | Download

AMA Style

Pattanapisansak T. Effect of Dihydropyridine Calcium Channel Blockers (CCB) on the Progression of Diabetic Nephropathy in Aranyaprathet Hospital, Sakeaw Province, Thailand. Am J Intern Med. 2024;12(3):33-39. doi: 10.11648/j.ajim.20241203.12

Copy | Download

@article{10.11648/j.ajim.20241203.12,
  author = {Teerapon Pattanapisansak},
  title = {Effect of Dihydropyridine Calcium Channel Blockers (CCB) on the Progression of Diabetic Nephropathy in Aranyaprathet Hospital, Sakeaw Province, Thailand
},
  journal = {American Journal of Internal Medicine},
  volume = {12},
  number = {3},
  pages = {33-39},
  doi = {10.11648/j.ajim.20241203.12},
  url = {https://doi.org/10.11648/j.ajim.20241203.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20241203.12},
  abstract = {Importance From Thailand, has standardized therapeutic drugs of Calcium channel blockers (CCB) in reduce the progression of chronic renal failure in diabetic and hypertension that is advantages for use in patients. However, use of Amlodipine that is more accessible and also a drug used by all community hospitals to treat patients, inexpensive and highly effective. Objective To study effective of Dihydropyridine Calcium channel blockers (CCB) on kidney function (eGFR), urinary protein creatinine and sugar blood level. Design, Setting, and Participants This study is retrospective cohort study by study in patients with diabetic nephropathy. By study in patients with diabetes nephropathy with stage 3 or higher and receiving Dihydropyridine Calcium channel blockers (CCB). Exposures Dihydropyridine Calcium channel blockers (CCB) in reducing the complications of diabetic nephropathy which is consistent with Strategy No.2 Providing quality and excellent health services. And literature reviews in Thailand have not found empirical evidence that mean Calcium Channel can reduce the complications of diabetic nephropathy. Main Outcomes and Measures The effectiveness of Dihydropyridine Calcium channel blockers (CCB) increases the complications of diabetic nephropathy. Results In volunteer, female patient proportion was 69.0%. Average age was 69.3 (± 9.69), minimum age is 40 years, maximum age is 97 years. Most patients were between 60-79 years, follow by 40-59 years follow by16.8% and more than 80 years 16.1%. In congenital disease, kidney disease, kidney failure, diabetes and hypertension are 100%, follow by 24% obesity and 0.2% cancer. The effect of Dihydropyridine Calcium channel blockers (CCB) on kidney function (eGFR), urine microalbumin and creatinine when compare with use drug CCB 2 groups including Amlodipine and Amlodipine+enalapril/losartan/valsartan. Found that volunteer that received CCB drug compare with month 3 and 12, the level of eGFR decreases (t=1.085) and Urine Microalbumin increases (t=1.496) by statistically significance (P = 0.002) and Dihydropyridine Calcium channel blockers (CCB) on Fasting blood sugar compares with month 3 and 12, Fasting blood sugar (t = 0.566) and HbA1C (t=0.677) was typically decreased significantly (P Conclusions and Relevance Calcium channel blockers (CCBs) was decline kidney function (decrease eGFR) and CCB leads to the decrease of eGFR and provides monitoring of CCB use, as this may lead to the decrease of kidney function.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Effect of Dihydropyridine Calcium Channel Blockers (CCB) on the Progression of Diabetic Nephropathy in Aranyaprathet Hospital, Sakeaw Province, Thailand

AU  - Teerapon Pattanapisansak
Y1  - 2024/09/11
PY  - 2024
N1  - https://doi.org/10.11648/j.ajim.20241203.12
DO  - 10.11648/j.ajim.20241203.12
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 33
EP  - 39
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20241203.12
AB  - Importance From Thailand, has standardized therapeutic drugs of Calcium channel blockers (CCB) in reduce the progression of chronic renal failure in diabetic and hypertension that is advantages for use in patients. However, use of Amlodipine that is more accessible and also a drug used by all community hospitals to treat patients, inexpensive and highly effective. Objective To study effective of Dihydropyridine Calcium channel blockers (CCB) on kidney function (eGFR), urinary protein creatinine and sugar blood level. Design, Setting, and Participants This study is retrospective cohort study by study in patients with diabetic nephropathy. By study in patients with diabetes nephropathy with stage 3 or higher and receiving Dihydropyridine Calcium channel blockers (CCB). Exposures Dihydropyridine Calcium channel blockers (CCB) in reducing the complications of diabetic nephropathy which is consistent with Strategy No.2 Providing quality and excellent health services. And literature reviews in Thailand have not found empirical evidence that mean Calcium Channel can reduce the complications of diabetic nephropathy. Main Outcomes and Measures The effectiveness of Dihydropyridine Calcium channel blockers (CCB) increases the complications of diabetic nephropathy. Results In volunteer, female patient proportion was 69.0%. Average age was 69.3 (± 9.69), minimum age is 40 years, maximum age is 97 years. Most patients were between 60-79 years, follow by 40-59 years follow by16.8% and more than 80 years 16.1%. In congenital disease, kidney disease, kidney failure, diabetes and hypertension are 100%, follow by 24% obesity and 0.2% cancer. The effect of Dihydropyridine Calcium channel blockers (CCB) on kidney function (eGFR), urine microalbumin and creatinine when compare with use drug CCB 2 groups including Amlodipine and Amlodipine+enalapril/losartan/valsartan. Found that volunteer that received CCB drug compare with month 3 and 12, the level of eGFR decreases (t=1.085) and Urine Microalbumin increases (t=1.496) by statistically significance (P = 0.002) and Dihydropyridine Calcium channel blockers (CCB) on Fasting blood sugar compares with month 3 and 12, Fasting blood sugar (t = 0.566) and HbA1C (t=0.677) was typically decreased significantly (P Conclusions and Relevance Calcium channel blockers (CCBs) was decline kidney function (decrease eGFR) and CCB leads to the decrease of eGFR and provides monitoring of CCB use, as this may lead to the decrease of kidney function.

VL  - 12
IS  - 3
ER  -

Copy | Download

Author Information

Teerapon Pattanapisansak

Medical Department, Aranyaprathet Hospital, Aranyaprathet, Thailand

Contact Email

http://orcid.org/0009-0004-8938-7420

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Pattanapisansak, T. (2024). Effect of Dihydropyridine Calcium Channel Blockers (CCB) on the Progression of Diabetic Nephropathy in Aranyaprathet Hospital, Sakeaw Province, Thailand. American Journal of Internal Medicine, 12(3), 33-39. https://doi.org/10.11648/j.ajim.20241203.12

Copy | Download

ACS Style

Pattanapisansak, T. Effect of Dihydropyridine Calcium Channel Blockers (CCB) on the Progression of Diabetic Nephropathy in Aranyaprathet Hospital, Sakeaw Province, Thailand. Am. J. Intern. Med. 2024, 12(3), 33-39. doi: 10.11648/j.ajim.20241203.12

Copy | Download

AMA Style

Pattanapisansak T. Effect of Dihydropyridine Calcium Channel Blockers (CCB) on the Progression of Diabetic Nephropathy in Aranyaprathet Hospital, Sakeaw Province, Thailand. Am J Intern Med. 2024;12(3):33-39. doi: 10.11648/j.ajim.20241203.12

Copy | Download

@article{10.11648/j.ajim.20241203.12,
  author = {Teerapon Pattanapisansak},
  title = {Effect of Dihydropyridine Calcium Channel Blockers (CCB) on the Progression of Diabetic Nephropathy in Aranyaprathet Hospital, Sakeaw Province, Thailand
},
  journal = {American Journal of Internal Medicine},
  volume = {12},
  number = {3},
  pages = {33-39},
  doi = {10.11648/j.ajim.20241203.12},
  url = {https://doi.org/10.11648/j.ajim.20241203.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20241203.12},
  abstract = {Importance From Thailand, has standardized therapeutic drugs of Calcium channel blockers (CCB) in reduce the progression of chronic renal failure in diabetic and hypertension that is advantages for use in patients. However, use of Amlodipine that is more accessible and also a drug used by all community hospitals to treat patients, inexpensive and highly effective. Objective To study effective of Dihydropyridine Calcium channel blockers (CCB) on kidney function (eGFR), urinary protein creatinine and sugar blood level. Design, Setting, and Participants This study is retrospective cohort study by study in patients with diabetic nephropathy. By study in patients with diabetes nephropathy with stage 3 or higher and receiving Dihydropyridine Calcium channel blockers (CCB). Exposures Dihydropyridine Calcium channel blockers (CCB) in reducing the complications of diabetic nephropathy which is consistent with Strategy No.2 Providing quality and excellent health services. And literature reviews in Thailand have not found empirical evidence that mean Calcium Channel can reduce the complications of diabetic nephropathy. Main Outcomes and Measures The effectiveness of Dihydropyridine Calcium channel blockers (CCB) increases the complications of diabetic nephropathy. Results In volunteer, female patient proportion was 69.0%. Average age was 69.3 (± 9.69), minimum age is 40 years, maximum age is 97 years. Most patients were between 60-79 years, follow by 40-59 years follow by16.8% and more than 80 years 16.1%. In congenital disease, kidney disease, kidney failure, diabetes and hypertension are 100%, follow by 24% obesity and 0.2% cancer. The effect of Dihydropyridine Calcium channel blockers (CCB) on kidney function (eGFR), urine microalbumin and creatinine when compare with use drug CCB 2 groups including Amlodipine and Amlodipine+enalapril/losartan/valsartan. Found that volunteer that received CCB drug compare with month 3 and 12, the level of eGFR decreases (t=1.085) and Urine Microalbumin increases (t=1.496) by statistically significance (P = 0.002) and Dihydropyridine Calcium channel blockers (CCB) on Fasting blood sugar compares with month 3 and 12, Fasting blood sugar (t = 0.566) and HbA1C (t=0.677) was typically decreased significantly (P Conclusions and Relevance Calcium channel blockers (CCBs) was decline kidney function (decrease eGFR) and CCB leads to the decrease of eGFR and provides monitoring of CCB use, as this may lead to the decrease of kidney function.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Effect of Dihydropyridine Calcium Channel Blockers (CCB) on the Progression of Diabetic Nephropathy in Aranyaprathet Hospital, Sakeaw Province, Thailand

AU  - Teerapon Pattanapisansak
Y1  - 2024/09/11
PY  - 2024
N1  - https://doi.org/10.11648/j.ajim.20241203.12
DO  - 10.11648/j.ajim.20241203.12
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 33
EP  - 39
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20241203.12
AB  - Importance From Thailand, has standardized therapeutic drugs of Calcium channel blockers (CCB) in reduce the progression of chronic renal failure in diabetic and hypertension that is advantages for use in patients. However, use of Amlodipine that is more accessible and also a drug used by all community hospitals to treat patients, inexpensive and highly effective. Objective To study effective of Dihydropyridine Calcium channel blockers (CCB) on kidney function (eGFR), urinary protein creatinine and sugar blood level. Design, Setting, and Participants This study is retrospective cohort study by study in patients with diabetic nephropathy. By study in patients with diabetes nephropathy with stage 3 or higher and receiving Dihydropyridine Calcium channel blockers (CCB). Exposures Dihydropyridine Calcium channel blockers (CCB) in reducing the complications of diabetic nephropathy which is consistent with Strategy No.2 Providing quality and excellent health services. And literature reviews in Thailand have not found empirical evidence that mean Calcium Channel can reduce the complications of diabetic nephropathy. Main Outcomes and Measures The effectiveness of Dihydropyridine Calcium channel blockers (CCB) increases the complications of diabetic nephropathy. Results In volunteer, female patient proportion was 69.0%. Average age was 69.3 (± 9.69), minimum age is 40 years, maximum age is 97 years. Most patients were between 60-79 years, follow by 40-59 years follow by16.8% and more than 80 years 16.1%. In congenital disease, kidney disease, kidney failure, diabetes and hypertension are 100%, follow by 24% obesity and 0.2% cancer. The effect of Dihydropyridine Calcium channel blockers (CCB) on kidney function (eGFR), urine microalbumin and creatinine when compare with use drug CCB 2 groups including Amlodipine and Amlodipine+enalapril/losartan/valsartan. Found that volunteer that received CCB drug compare with month 3 and 12, the level of eGFR decreases (t=1.085) and Urine Microalbumin increases (t=1.496) by statistically significance (P = 0.002) and Dihydropyridine Calcium channel blockers (CCB) on Fasting blood sugar compares with month 3 and 12, Fasting blood sugar (t = 0.566) and HbA1C (t=0.677) was typically decreased significantly (P Conclusions and Relevance Calcium channel blockers (CCBs) was decline kidney function (decrease eGFR) and CCB leads to the decrease of eGFR and provides monitoring of CCB use, as this may lead to the decrease of kidney function.

VL  - 12
IS  - 3
ER  -

Copy | Download